On May 21, 2025, Aytu BioPharma approved an amendment increasing the shares in its 2023 Equity Incentive Plan by 300,000 to a total of 500,000 shares. Additionally, all incumbent directors were re-elected, and other proposals regarding accounting firm appointments and executive compensation were also approved.